22 July 2024
22 July 2024
The approval extends the use of Inspire therapy beyond the previously allowed head, neck, and extremity MRI scans.
The Nasdaq notice indicates that the company has 180 days to regain compliance with the minimum bid price requirement.
The upgraded Biosen C-Line device is intended for accurate measurement of glucose and lactate levels.
The GTT@home test allows expectant mothers to complete the OGTT remotely.
The Phase III trial of EDAP’s robotic ultrasound therapy will continue as the three-month interim follow-up period is deemed “too short” to meet the endpoint.
Pulsed field ablation catheters are becoming physicians’ preferred choice.
The company still dominates the endotracheal tube market, but the incident is expected to have a noticeable effect on future sales.
Results from Microbot's trial will be used to support future marketing submissions to the FDA.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest thematic intelligence report discusses the mHealth software technologies and the emerging trends that will impact the use of these apps in the healthcare industry in the coming years. The report also covers value chain insights, key players, and sector scorecard analysis. While there are several categories of mHealth apps, our report will focus on medical apps, which are regulated and generally need a prescription or corresponding device to use.
Give your business an edge with our leading industry insights.
